Biopharma major Biocon is planning to set up a dedicated greenfield facility to manufacture tablet formulations. The Bangalore-based company currently outsources this activity. Biocon is in the tablet formulation market in a small way now across the nephrology, diabetology, cardiology and oncology verticals. This segment accounts for about 10% of Biocons revenues, which it hopes to more than double to 25% in the next three to four years with its own manufacturing facility. Biocon manufactures its own injectable formulations across all bio-pharma verticals that it operates in.